The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells

Breast Cancer Research and Treatment

Volumn 58, Issue 2, 1999, Pages 87-97

  Diel, Patrick ^a   Smolnikar, Kai ^a   Michna, Horst ^a  

^a DSHS Cologne ^*  (Germany)

Author keywords

Antiestrogens; Apoptosis; BCL 2; Breast cancer; MCF 7; Tamoxifen; ZM 182780

Indexed keywords

ANTIESTROGEN; ESTROGEN; FULVESTRANT; PROTEIN BCL 2; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033426829     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006338123126     Document Type: Article

References (36)

1. 1. Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984
2. 2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529, 1995
3. 3. Morrow M, Jordan VC: Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg 128: 1187-1191, 1993
4. 4. Tonetti DA, Jordan VC: Possible mechanisms in the emergence of tamoxifenresistant breast cancer. Anticancer Drugs 6: 498-507, 1995
5. 5. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A: 1714-1721, 1994
6. 6. Assikis VJ, Neven P, Jordan VC, Vergote I: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A: 1464-1476, 1996
7. 7. Bilimoria MM, Assikis VJ, Jordan VC: Should adjuvant tamoxifen therapy be stopped at 5 Years? Cancer J Sci Am 2: 140-150, 1996
8. 8. Wakeling AE: A new approach to breast cancer therapy - total estrogen ablation with pure antiestrogen. In: Jordan VC (ed) Long-Term Tamoxifen Treatment for Breast Cancer. Madison W, University of Wisconsin, 1994, pp 219-234
9. 9. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750, 1995
10. 10. Gradishar WJ, Jordan VC: Clinical potential of new antiestrogens. J Clin Oncol 15: 840-852, 1997
11. 11. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991
12. 12. Wilson JW, Wakeling AE, Morris ID, Hickman JA, Dive C: MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int J Cancer 61: 502-508, 1995
13. 13. Kerr JF, Wyllic AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972
14. 14. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: BCL-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990
15. 15. Garcia I, Martinou I, Tsujimoto Y, Martinou JC: Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 258: 302-304, 1992
16. 16. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994
17. 17. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini AM: Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behavior. Ann Oncol 6: 275-282, 1995
18. 18. Wang TT, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995
19. 19. Michna H, Schneider MR, Nishino Y, El Etreby MF: Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14: 275-288, 1989
20. 20. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning - A Laboratory Manual, 2nd edition. Cold Spring Harbor Laboratory, Cold Spring Habor, 1989
21. 21. Murphy I.D, Herzog CE, Rudick JB, Fojo AT, Bates SE: Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29: 10351-10356, 1990
22. 22. Knauthe R, Diel P, Hegele-Hartung C, Engelhaupt A, Fritzemeier KH: Sexual dimorphism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology 137: 3220-3227, 1996
23. 23. Warri AM, Huovinen RL, Laine AM, Martikainen PM, Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro, J Natl Cancer Inst 85: 1412-1418, 1993
24. 24. Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166, 1991
25. 25. Bursch W, Ellinger A, Kienzl H, Torok L, Pandey S, Sikorska M, Walker R, Hermann RS: Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17: 1595-1607, 1996
26. 26. Perry RR, Kang Y, Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995
27. 27. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M: Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72: 608-613, 1997
28. 28. Oltvai ZN, Milliman CL, Korsmeyer SJ: BCL-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993
29. 29. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854-859, 1995
30. 30. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69: 135-139, 1994
31. 31. Adam L, Crepin M, Israel L: Tumor growth inhibition, apoptosis, and BCL-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res 57: 1023-1029, 1997
32. 32. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Compel A: Antagonism between estradiol and progestin on BCL-2 expression in breast-cancer cells. Int J Cancer 68: 120-125, 1996
33. 33. Gibson MK, Nemmers LA, Beckman WC Jr, Davis VL, Curtis SW, Korach KS: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010, 1991
34. 34. Dauvois S, White R, Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377-1388, 1993
35. 35. Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742-1751, 1978
36. 36. Savouret JF, Bailly A, Misrahi M, Rauch C, Redeuilh G, Chauchereau A, Milgrom E: Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J 10: 1875-1883, 1991